Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis

M.P. Namaka, D.A. Turcotte, M. Klowak, C.M. Leong, A. Grossberndt, J-A. Le Dorze, M.E. Prout, S. Andresen, L. Vuong, M.J. Melanson, E.E. Frost, M. Doupe
2011 Clinical Medicine Insights: Therapeutics  
and purpose: Mitoxantrone (MX) (Novantrone ® ) is approved in Canada for certain refractory cancers and acute nonlymphocytic leukemias. It has FDA approval as an immunomodulatory agent for use in secondary progressive multiple sclerosis (SPMS). The general aim of this study is to evaluate the efficacy, safety, and tolerability of MX in SPMS. Experimental approach: A single-centre, open-label, non-randomized study was conducted in patients with a $6 month history of SPMS. The primary parameters
more » ... sed to assess efficacy and safety were EDSS scores and the multiple-gated acquisition scan (MUGA) scores, respectively.
doi:10.4137/cmt.s7586 fatcat:rzt6tbuvmbe6jc4hswkagczxne